Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

570 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of regorafenib compared to placebo and to post-cross-over regorafenib in advanced non-adipocytic soft tissue sarcoma.
Brodowicz T, Mir O, Wallet J, Italiano A, Blay JY, Bertucci F, Eisterer W, Chevreau C, Piperno-Neumann S, Bompas E, Ryckewaert T, Liegl-Antzwager B, Thery J, Penel N, Le Cesne A, Le Deley MC. Brodowicz T, et al. Among authors: bertucci f. Eur J Cancer. 2018 Aug;99:28-36. doi: 10.1016/j.ejca.2018.05.008. Epub 2018 Jun 11. Eur J Cancer. 2018. PMID: 29902612 Clinical Trial.
Identification of biological factors predictive of response to imatinib mesylate in aggressive fibromatosis.
Dufresne A, Bertucci F, Penel N, Le Cesne A, Bui B, Tubiana-Hulin M, Ray-Coquard I, Cupissol D, Chevreau C, Perol D, Goncalves A, Jimenez M, Bringuier PP, Blay JY. Dufresne A, et al. Among authors: bertucci f. Br J Cancer. 2010 Aug 10;103(4):482-5. doi: 10.1038/sj.bjc.6605783. Epub 2010 Jul 27. Br J Cancer. 2010. PMID: 20664593 Free PMC article. Clinical Trial.
Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial.
Le Cesne A, Ray-Coquard I, Bui BN, Adenis A, Rios M, Bertucci F, Duffaud F, Chevreau C, Cupissol D, Cioffi A, Emile JF, Chabaud S, Pérol D, Blay JY; French Sarcoma Group. Le Cesne A, et al. Among authors: bertucci f. Lancet Oncol. 2010 Oct;11(10):942-9. doi: 10.1016/S1470-2045(10)70222-9. Epub 2010 Sep 21. Lancet Oncol. 2010. PMID: 20864406 Clinical Trial.
Metastatic angiosarcomas: doxorubicin-based regimens, weekly paclitaxel and metastasectomy significantly improve the outcome.
Penel N, Italiano A, Ray-Coquard I, Chaigneau L, Delcambre C, Robin YM, Bui B, Bertucci F, Isambert N, Cupissol D, Bompas E, Bay JO, Duffaud F, Guillemet C, Blay JY; French Sarcoma Group (GSF/GETO). Penel N, et al. Among authors: bertucci f. Ann Oncol. 2012 Feb;23(2):517-23. doi: 10.1093/annonc/mdr138. Epub 2011 May 12. Ann Oncol. 2012. PMID: 21566149 Free article.
Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas.
Italiano A, Cioffi A, Penel N, Levra MG, Delcambre C, Kalbacher E, Chevreau C, Bertucci F, Isambert N, Blay JY, Bui B, Antonescu C, D'Adamo DR, Maki RG, Keohan ML. Italiano A, et al. Among authors: bertucci f. Cancer. 2012 Jul 1;118(13):3330-6. doi: 10.1002/cncr.26599. Epub 2011 Nov 1. Cancer. 2012. PMID: 22045619 Free article.
Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era.
Cassier PA, Fumagalli E, Rutkowski P, Schöffski P, Van Glabbeke M, Debiec-Rychter M, Emile JF, Duffaud F, Martin-Broto J, Landi B, Adenis A, Bertucci F, Bompas E, Bouché O, Leyvraz S, Judson I, Verweij J, Casali P, Blay JY, Hohenberger P; European Organisation for Research and Treatment of Cancer. Cassier PA, et al. Among authors: bertucci f. Clin Cancer Res. 2012 Aug 15;18(16):4458-64. doi: 10.1158/1078-0432.CCR-11-3025. Epub 2012 Jun 20. Clin Cancer Res. 2012. PMID: 22718859
A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study). A study of the French Sarcoma Group.
Pautier P, Floquet A, Gladieff L, Bompas E, Ray-Coquard I, Piperno-Neumann S, Selle F, Guillemet C, Weber B, Largillier R, Bertucci F, Opinel P, Duffaud F, Reynaud-Bougnoux A, Delcambre C, Isambert N, Kerbrat P, Netter-Pinon G, Pinto N, Duvillard P, Haie-Meder C, Lhommé C, Rey A. Pautier P, et al. Among authors: bertucci f. Ann Oncol. 2013 Apr;24(4):1099-104. doi: 10.1093/annonc/mds545. Epub 2012 Nov 8. Ann Oncol. 2013. PMID: 23139262 Free article. Clinical Trial.
Influence of imatinib interruption and rechallenge on the residual disease in patients with advanced GIST: results of the BFR14 prospective French Sarcoma Group randomised, phase III trial.
Patrikidou A, Chabaud S, Ray-Coquard I, Bui BN, Adenis A, Rios M, Bertucci F, Duffaud F, Chevreau C, Cupissol D, Domont J, Pérol D, Blay JY, Le Cesne A; French Sarcoma Group. Patrikidou A, et al. Among authors: bertucci f. Ann Oncol. 2013 Apr;24(4):1087-93. doi: 10.1093/annonc/mds587. Epub 2012 Nov 21. Ann Oncol. 2013. PMID: 23175622 Free article. Clinical Trial.
570 results